Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee

Proposed treatment for elevated intraocular pressure would be first in new rho-associated protein kinase inhibitor class.

Eye — In addition to stand-alone treatment for intraocular pressure, Aerie also wants to combine netarsudil with latanoprost for use in glaucoma.

Aerie Pharmaceuticals Inc. may have to overcome safety concerns in trying to gain approval for the first in a new class of drugs to treatment of elevated intraocular pressure.

The company has proposed once-daily netarsudil, proposed trade name Rhopressa, for reduction of elevated intraocular pressure (IOP) in patients with...